H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 24.45 HKD 0.2%
Market Cap: 145.4B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Hansoh Pharmaceutical Group Company Ltd stock under the Base Case scenario is 17.33 HKD. Compared to the current market price of 24.45 HKD, Hansoh Pharmaceutical Group Company Ltd is Overvalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
17.33 HKD
Overvaluation 29%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

11
P/S
P/S
Price to Sales
11
vs History
28
vs Industry
15
Median 3Y
8
Median 5Y
8.6
Industry
2.4
Forward
9.9
More Details
30.9
P/E
P/E
Price to Earnings
30.9
vs History
36
vs Industry
19
Median 3Y
26.2
Median 5Y
29.3
Industry
20.3
Forward
29.7
More Details
29
P/OCF
P/OCF
Price to OCF
29
vs History
47
vs Industry
17
Median 3Y
25.5
Median 5Y
28.8
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
15
Median 3Y
27.2
Median 5Y
29.1
Industry
23.1
More Details
4.7
P/B
P/B
Price to Book Value
4.7
vs History
30
vs Industry
18
Median 3Y
3.4
Median 5Y
3.8
Industry
2
More Details
9.1
EV/S
EV/S
Enterprise Value to Sales
9.1
vs History
28
vs Industry
17
Median 3Y
6.1
Median 5Y
6.5
Industry
2.5
Forward
8.2
More Details
10
EV/GP
EV/GP
Enterprise Value to Gross Profit
10
vs History
28
vs Industry
25
Median 3Y
6.7
Median 5Y
7.1
Industry
4.8
More Details
20.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.5
vs History
42
vs Industry
18
Median 3Y
18.3
Median 5Y
20.3
Industry
12.5
Forward
22.7
More Details
22.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
22.1
vs History
52
vs Industry
20
Median 3Y
20.6
Median 5Y
22.4
Industry
15.7
Forward
24.1
More Details
24
EV/OCF
EV/OCF
Enterprise Value to OCF
24
vs History
39
vs Industry
22
Median 3Y
19.2
Median 5Y
22.1
Industry
14.1
More Details
26.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
26.6
vs History
41
vs Industry
21
Median 3Y
21.4
Median 5Y
24.5
Industry
17.6
More Details
13.9
EV/IC
EV/IC
Enterprise Value to IC
13.9
vs History
26
vs Industry
8
Median 3Y
7.7
Median 5Y
8.8
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Hansoh Pharmaceutical Group Company Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
145.1B HKD 11 30.9 20.5 22.1
US
Eli Lilly and Co
NYSE:LLY
734.6B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.6 26.1 9.8 11.4
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4 28.5 131.6 198.5
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.1B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
CN
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Average P/E: 25.1
30.9
8%
3.9
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Average EV/EBITDA: 395.8
20.5
3%
6.8
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
131.6
9%
14.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Average EV/EBIT: 1 699
22.1
4%
5.5
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
198.5
21%
9.5
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.